{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:05:52Z","timestamp":1792785952477,"version":"4.5.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T00:00:00Z","timestamp":1608595200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Mectizan Donation Program"},{"name":"Global Alliance for LF Elimination"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>World Health Assembly Resolution 50.29, adopted in 1997, committed the World Health Organization (WHO) and its member states to eliminate lymphatic filariasis (LF) as a public health problem. In 2000, to support this ambitious goal and the health ministries in the &amp;gt;70 LF-endemic countries, the Global Programme to Eliminate Lymphatic Filariasis (GPELF) was created. The resulting WHO elimination strategy consists of two main components: to stop the spread of infection by interrupting transmission and to alleviate the suffering of affected populations (by controlling morbidity). The GPELF has brought together a broad global partnership of public and private actors, including three pharmaceutical companies with headquarters in three different continents. The medicine donations programmes from GlaxoSmithKline, MSD (trade name of Merck &amp; Co. Inc., Kenilworth, NJ, USA) and Eisai have enabled significant achievements during the first 20\u00a0y of the GPELF and are positioned to provide essential contributions to the GPELF's goals for the next decade. As we celebrate the progress towards LF elimination during the GPELF's first 20\u00a0y, this article reflects on the factors that led to the creation of the three donation programmes, the contributions these programmes have made and some lessons learned along the way. We close by emphasizing our continued commitments to LF elimination and perspectives on the next decade.<\/jats:p>","DOI":"10.1093\/inthealth\/ihaa077","type":"journal-article","created":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T07:52:08Z","timestamp":1600847528000},"page":"S39-S43","source":"Crossref","is-referenced-by-count":7,"title":["The role of medicine donations in the global programme for the elimination of lymphatic filariasis"],"prefix":"10.1093","volume":"13","author":[{"given":"Tijana","family":"Williams","sequence":"first","affiliation":[{"name":"Global Health Unit, GSK, 980 Great West Road, Brentford, Middlesex, TW8\u00a09GS, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Taylor","sequence":"additional","affiliation":[{"name":"Corporate Responsibility, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minne","family":"Iwamoto","sequence":"additional","affiliation":[{"name":"Global Health Unit, GSK, 980 Great West Road, Brentford, Middlesex, TW8\u00a09GS, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Hida","sequence":"additional","affiliation":[{"name":"Sustainability, Eisai Co., Ltd., 4-6-10 Koishikawa, Bunkyo-ku, Tokyo 1128088, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Gusovsky","sequence":"additional","affiliation":[{"name":"Global Health Research, hDAC Eisai Inc., 35 Cambridgepark Drive, Cambridge, MA 02140 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,12,22]]},"reference":[{"issue":"1 Suppl 2","key":"2021031906231119800_bib1","first-page":"3","article-title":"History, epidemiology and control of filariasis","volume":"39","author":"Otsuji","year":"2011","journal-title":"Trop Med Health"},{"issue":"20","key":"2021031906231119800_bib2","first-page":"149","article-title":"Global programme to eliminate lymphatic filariasis: progress report","volume":"76","author":"World Health Organization","year":"2001","journal-title":"Wkly Epidemiol Rec."},{"key":"2021031906231119800_bib3","volume-title":"Lymphatic filariasis: global programme to eliminate lymphatic filariasis","author":"World Health Organization"},{"issue":"1","key":"2021031906231119800_bib4","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S0035-9203(98)90972-5","article-title":"Efficacy of single dose combinations of albendazole, ivermectin and diethylcarbamazine for the treatment of bancroftian filariasis","volume":"92","author":"Ismail","year":"1998","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"Suppl 1","key":"2021031906231119800_bib5","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.actatropica.2010.09.009","article-title":"Evaluation of effectiveness of diethylcarbamazine\/albendazole combination in reduction of Wuchereria bancrofti infection using multiple infection parameters","volume":"120","author":"Wamaea","year":"2011","journal-title":"Acta Trop."},{"issue":"9","key":"2021031906231119800_bib6","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S0169-4758(99)01486-6","article-title":"The role of albendazole in programmes to eliminate lymphatic filariasis","volume":"5","author":"Ottesen","year":"1999","journal-title":"Parasitol Today"},{"issue":"6","key":"2021031906231119800_bib7","first-page":"491","article-title":"Strategies and tools for the control\/elimination of lymphatic filariasis","volume":"75","author":"Ottesen","year":"1997","journal-title":"Bull World Health Org"},{"key":"2021031906231119800_bib8","volume-title":"What is the program?","author":"Mectizan Donation Program"},{"key":"2021031906231119800_bib9","article-title":"Major private sector partner, Merck, welcomed to lymphatic filariasis control effort","author":"World Health Organisation","year":"1998"},{"key":"2021031906231119800_bib10","article-title":"WHO and SmithKline Beecham to cooperate on elephantiasis elimination","author":"World Health Organisation","year":"1998"},{"key":"2021031906231119800_bib11","first-page":"457","article-title":"Global programme to eliminate lymphatic filariasis: progress report, 2017","volume-title":"Wkly Epidemiol Rec.","author":"World Health Organisation","year":"2017"},{"issue":"Suppl 1","key":"2021031906231119800_bib12","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1179\/000349809X12502035776478","article-title":"GlaxoSmithKline and Merck: private-sector collaboration for the elimination of lymphatic filariasis","volume":"103","author":"Gustavsen","year":"2009","journal-title":"Ann Trop Med Parasitol"},{"key":"2021031906231119800_bib13","first-page":"R1","article-title":"Diethylcarbamazine: a review of its action in onchocerciasis, lymphatic filariasis and inflammation","volume":"82","author":"Mackenzie","year":"1998","journal-title":"Trop Dis Bull"},{"issue":"9973","key":"2021031906231119800_bib14","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/S0140-6736(15)60301-4","article-title":"The theory of everything and a neglected tropical disease: a Hawking legacy","volume":"385","author":"Molyneux","year":"2015","journal-title":"Lancet"},{"issue":"12","key":"2021031906231119800_bib15","doi-asserted-by":"crossref","first-page":"e3328","DOI":"10.1371\/journal.pntd.0003328","article-title":"Global programme to eliminate lymphatic filariasis: the processes underlying programme success","volume":"8","author":"Ichimori","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"2021031906231119800_bib16","first-page":"489","article-title":"Global programme to eliminate lymphatic filariasis: progress report, 2014","volume-title":"Wkly Epidemiol Rec","author":"World Health Organisation","year":"2015"},{"issue":"19","key":"2021031906231119800_bib17","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1706854","article-title":"A trial of a triple-drug treatment for lymphatic filariasis","volume":"379","author":"King","year":"2018","journal-title":"N Engl J Med"},{"key":"2021031906231119800_bib18","volume-title":"WHO guideline: alternative mass drug administration regimens to eliminate lymphatic filariasis","author":"World Health Organization","year":"2017"},{"key":"2021031906231119800_bib19","volume-title":"Ending the neglect to attain the sustainable development goals: a road map for neglected tropical diseases 2021\u20132030","author":"World Health Organization","year":"2020"},{"key":"2021031906231119800_bib20","article-title":"The NTD Supply Chain Forum \u2014 strengthening the backbone of NTD programs globally","author":"Ashley","year":"2020"},{"issue":"6","key":"2021031906231119800_bib21","first-page":"728","article-title":"Investment success in public health: an analysis of the cost-effectiveness and cost-benefit of the global programme to eliminate lymphatic filariasis","volume":"64","author":"Turner","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2021031906231119800_bib22","article-title":"Past, present and future: medicine donation programmes supporting the global drive to end the burden of neglected tropical diseases","author":"Bradley","year":"2020","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2021031906231119800_bib23","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s40249-020-00701-7","article-title":"Strategies supporting the prevention and control of neglected tropical diseases during and beyond the COVID-19 pandemic","volume":"9","author":"Ehrenberg","year":"2020","journal-title":"Infect Dis Poverty"},{"issue":"5","key":"2021031906231119800_bib24","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/inthealth\/ihaa040","article-title":"COVID-19 and neglected tropical diseases in Africa: impacts, interactions, consequences","volume":"12","author":"Molyneux","year":"2020","journal-title":"Int Health"},{"key":"2021031906231119800_bib25","volume-title":"WHO PCT Databank","author":"World Health Organization"}],"container-title":["International Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/inthealth\/article-pdf\/13\/Supplement_1\/S39\/36643601\/ihaa077.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/inthealth\/article-pdf\/13\/Supplement_1\/S39\/36643601\/ihaa077.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T02:23:44Z","timestamp":1616120624000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/inthealth\/article\/13\/Supplement_1\/S39\/6043668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,22]]},"references-count":25,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2020,12,22]]},"published-print":{"date-parts":[[2020,12,22]]}},"URL":"https:\/\/doi.org\/10.1093\/inthealth\/ihaa077","relation":{},"ISSN":["1876-3413","1876-3405"],"issn-type":[{"value":"1876-3413","type":"print"},{"value":"1876-3405","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,1]]},"published":{"date-parts":[[2020,12,22]]}}}